Navigation Links
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC) Intergroup Study Results

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC study, demonstrate for the first time that peri-operative (pre and post surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) in combination with a standard chemotherapy regimen for colon cancer, 5-fluorouracil/leucovorin (5-FU/LV)) given to patients with resectable liver metastases from colorectal cancer significantly improved Progression-Free Survival (PFS) compared to surgery alone. (PFS is the time from the start of therapy until disease progression or death). The EPOC study results were presented today at the Plenary Session of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

At a median follow-up of three years, FOLFOX4 treatment given before and after surgery significantly improved PFS by 9.2% and reduced the risk of relapse by 27% (HR=0.73, p=0.025) among patients for whom resection was successful. When evaluating results among all randomized patients, including the 61 patients who were not able to undergo liver metastases resection or were ineligible, FOLFOX4 did not significantly improve PFS compared to surgery alone (7.2% absolute difference, p=0.058). However, when taking into account all eligible patients (171 in each arm), even those not resected, FOLFOX4 treatment significantly improved PFS by 8.1% and reduced the risk of relapse by 23% (H=0.77, CI:0.60-1.00 ; p=0.041).Results showed that FOLFOX4 given before resection did not prevent patients' ability to undergo surgery.

The most common adverse events were with preoperative chemotherapy: diarrhea (Grade3: 8.2%), sensory neuropathy (Grade3: 2.3%), neutropenia (Grade3/4:18.1%); and with post-operative chemotherapy: sensory neuropathy (Grade3: 9.6%), neutropenia (Grade3/4: 34.8%). The
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
2. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
11. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
Post Your Comments:
(Date:10/31/2014)... -- Digirad Corporation (Nasdaq: DRAD) today announced that it has sent ... ), a healthcare commercialization services company, responding to PDI,s ... Digirad calls upon PDI to immediately ... operate in the ordinary course of business and to ... on acquisitions or other extraordinary transactions. Digirad believes that ...
(Date:10/31/2014)... DIEGO, Oct. 31, 2014 Mast Therapeutics, Inc. ... financial results for the quarter ended September 30, 2014. ... Executive Officer, said:  "The third quarter was productive for ... study of MST-188 for sickle cell disease is on ... year. We now have opened 50 study sites in the ...
(Date:10/31/2014)... 2014 Today, Analysts Review released ... CELG ), Bristol-Myers Squibb Co. (NYSE: BMY ... Sanofi SA (NYSE: SNY ) and Actavis ... ahead of publication. To reserve complementary membership, limited openings ... Corporation Research Reports ,On October 23, 2014, Celgene Corporation ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... 2011 A coalition of advocacy groups and patients yesterday ... District of Columbia Circuit to compel the Obama Administration to ... under the provisions of the Controlled Substances Act (CSA). ... states with medical marijuana laws to expedite efforts to change ...
... 24, 2011 American Scientific Resources, Incorporated (OTCQB: ... with the S.E.C. containing results for the quarter ... http://www.sec.gov/Archives/edgar/data/1114605/000114420411031846/0001144204-11-031846-index.htm to review the entire 10-Q filing. ... The Company would also like to direct investors ...
Cached Medicine Technology:Federal Court Asked to Compel Decision in Marijuana Scheduling Action 2Federal Court Asked to Compel Decision in Marijuana Scheduling Action 3American Scientific Resources, Inc. Announces Quarterly Results 2
(Date:11/1/2014)... Tara Haelle HealthDay Reporter ... can both sense adult anger and alter their behavior in ... sponges," said study co-author Andrew Meltzoff, co-director of the University ... "They learn not only from their own direct social experiences ... He said he was most surprised at how emotionally ...
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... of duration of treatment and cost, patients with ... partial breast irradiation (APBI) with proton therapy versus ... from The University of Texas MD Anderson Proton ... analysis study based on typical patient characteristics, researchers ... for eight different types of partial and whole ...
Breaking Medicine News(10 mins):Health News:Study Shows How Toddlers Adjust to Adult Anger 2Health News:Study Shows How Toddlers Adjust to Adult Anger 3Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... , TUESDAY, Nov. 2 (HealthDay News) -- The U.S. Food ... properly monitoring the safety of medical devices, the authors of ... to approve both drugs and medical devices, but the investigators ... is lax in both its initial approval of devices and ...
... Ariz. Volunteering is known to provide health benefits ... study finds that older adults with functional limitations (trouble ... to reap the benefits from helping others. ... impact of volunteering on risk of mortality was stronger ...
... vaccination and health programs may help states improve their ... a new study suggests. The study -- conducted ... collaboration with the Centers for Disease Control and Prevention ... the striking state-by-state variation in U.S. H1N1 flu vaccination ...
... published in November 3 edition of Journal of ... MPH, MBA, professor of Health Policy and Management at ... for key improvements to primary care in order to ... adults with multiple chronic conditions. Boult and his co-author, ...
... Reporter , TUESDAY, Nov. 2 (HealthDay News) -- Only one in ... asthma symptoms in kids, a new study found. What,s ... symptom, according to the study, which was to be presented Nov. ... Physicians, in Vancouver, Canada. "We found that about 35 ...
... includes three articles with leading research, highlighted below. ... in Patients With Acute Coronary Syndrome ROCHESTER, ... present with acute coronary syndrome had significantly higher rates of ... risk profiles. "The leaves of khat, a leafy ...
Cached Medicine News:Health News: FDA Failing to Monitor Safety of Medical Devices: Report 2Health News: FDA Failing to Monitor Safety of Medical Devices: Report 3Health News: FDA Failing to Monitor Safety of Medical Devices: Report 4Health News:Study shows volunteering benefits those with functional limitations 2Health News:Study shows volunteering benefits those with functional limitations 3Health News:Strengthening routine flu vaccination and health programs may improve pandemic vaccinations 2Health News:Strengthening routine flu vaccination and health programs may improve pandemic vaccinations 3Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 2Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 3Health News:Many Coaches Unprepared for Student-Athletes' Asthma 2Health News:Many Coaches Unprepared for Student-Athletes' Asthma 3Health News:Mayo Clinic Proceedings: November highlights 2
... LP is a super-light polypropylene mesh which ... reaction is reduced considerably. Optilene Mesh LP ... open hernia repair procedures. It perfectly conforms,to ... Optilene Mesh LP adapts to the movements ...
... Premilene Mesh Self-Forming Plug is a mesh ... as well as primary inguinal hernias and ... the defect and fills it completely. Premilene ... made of the established Premilene Mesh. The ...
... The advanced optical system of the Applied ... of illumination. There are six models to ... spot options. Spot size ranges from 15 ... headlight system is compatible with any of ...
... The use of some micro vascular ... and thrombosis. With use, Stainless steel changes ... is known that pressures above 30g/mm2 may ... are made from titanium which does not ...
Medicine Products: